What is the use of Imatinib 400mg Tablet Imat?
Imatinib 400mg Tablet Imat 400 is used in the treatment of blood cancer and gastrointestinal stromal tumor.
Imatinib was endorsed for clinical use in the United States in 2001. It is on the World Health Organization’s List of Essential Medicines. A conventional adaptation opened up in the UK starting in 2017.
Imatinib is utilized to treat persistent myelogenous leukemia (CML), gastrointestinal stromal tumors (GISTs), and various malignancies. In 2006 the FDA used supported use to incorporate Dermatofibrosarcoma protuberans (DFSP), Myelodysplastic/myeloproliferative sicknesses (MDS/MPD), Aggressive foundational mastocytosis (ASM).
Side effects of Imatinib 400mg Tablet Imat:
The most common side effects of this medicine Imatinib 400mg Tablet Imat 400 include rash, vomiting, abdominal pain, and diarrhea. Other than this, water retention and swelling are commonly observed side effects. Let your doctor know if you experience unexpected rapid weight gain. Your doctor may advise regular monitoring of blood cells and liver function while taking this medicine. Do not drive or do anything requiring mental focus if you experience dizziness and blurry vision.
How Imatinib 400mg Tablet Imat can be used:
Imat 400mg Tablets should be taken with food, but it’s better to have it at the same time every day to get the most benefit. You should continue to take it as long as your doctor advises for it. The duration of treatment varies according to your needs and response to treatment. Taking it in the wrong way or taking too much can cause very serious side effects. It may take several weeks or months for you to see or feel the benefits but do not stop taking it unless your doctor tells you to. For more details, click here.
Trade Name:– Imat 400
Manufacturer: Zydus Cadila
Presentation: Tablets
Strength: 400mg
We are exporting medicines from India to different countries like the United Arab Emirates, United States, Brazil, Saudi Arabia, etc. If you are looking for another product or brand click here.
